Increased 18F-FDG uptake in degenerative disease of the spine: Characterization with 18F-FDG PET/CT

Journal of Nuclear Medicine

Volumn 47, Issue 8, 2006, Pages 1274-1280

  Rosen, Ron S ^a   Fayad, Laura ^a   Wahl, Richard L ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

18F FDG; CT; Degenerative spinal disease; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEGENERATIVE SPINAL DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; HUMAN; INTERVERTEBRAL DISK DEGENERATION; LUMBOSACRAL SPINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOLOGIST; RATING SCALE; RETROSPECTIVE STUDY; SPINAL CORD METASTASIS; SPINE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SPINAL DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33749049138     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography: clinical use, interpretationmethods, diagnostic improvements. Semin Nucl Med. 2003;33:228-237.
2. Wahl RL. Principles of cancer imaging with fluorodeoxyglucose. In: Wahl RL, Buchanan JW, eds. Principles and Practice of Positron Emission Tomography. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:100-110.
3. Bohdiewicz PJ, Wong CY, Kondas D, Gaskill M, Dworkin HJ. High predictive value of F-18 FDG PET patterns of the spine for metastases or benign lesions with good agreement between readers. Clin Nucl Med. 2003;28:966-970.
4. 18F-FDG PET/CT. J Nucl Med. 2004;45:279-284.
5. Stumpe KD, Zanetti M, Weishaupt D, Hodler J, Boos N, Von Schulthess GK. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR. 2002;179:1151-1157.
6. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging. 2002;29:516-524.
7. Schmitz A, Risse JH, Grunwald F, Gassel F, Biersack HJ, Scmitt O. Fluorine-18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: preliminary results. Eur Spine J. 2001;10:534-539.
8. Kalicke T, Schmitz A, Risse HJ, et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med. 2000;27:524-528.
9. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D glucose. Radiology. 1995;196:647-655.
10. Peterson C, Bolton J, Wood A, Humphreys BK. A cross-sectional study correlating degeneration of the cervical spine with disability and pain in United Kingdom patients. Spine. 2003;28:129-133.
11. Peterson CK, Bolton J, Wood A. A cross-sectional study correlating lumbar spine degeneration with disability and pain. Spine. 2000;25:218-223.
12. Speciale AC, Pietrobon R, Urban CW, et al. Observer variability in assessing lumbar spinal stenosis severity on magnetic resonance imaging and its relation to cross-sectional spinal canal area. Spine. 2002;27:1082-1086.
13. Drew B, Bhandari MK, Abhaya V, Louw D, Reddy K, Dunlop B. Reliability in grading the severity of lumbar spinal stenosis. J Spinal Disord. 2000;13:253-258.
14. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998;25:1244-1247.
15. Sugawara Y. Infection and inflammation. In: Wahl RL, Buchanan JW, eds. Principles and Practice of Positron Emission Tomography. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:381-394.
16. 125I-HAS. Eur J Nucl Med. 1999;26:333-341.
17. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47-59.
18. Bakheet SM, Saleem M, Powe J, et al. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med. 2000;25:273-278.
19. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185-191.
20. Daley JM, Shearer JD, Mastrofrancesco B, et al. Glucose metabolism in injured tissue: a longitudinal study. Surgery. 1990;107:187-192.
21. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
22. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med. 1995;20:434-435.
23. Bicik I, Bauerfeind P, Breitbach T, et al. Inflammatory bowel disease activity measured by positron-emission tomography [letter]. Lancet. 1997;350:262.
24. Yasuda S, Shohtsu A, Ide M, et al. F-18 FDG accumulation in inflamed joints. Clin Nucl Med. 1996;21:740.
25. 18F-FDG PET. J Nucl Med. 2004;45:956-964.
26. 18F-FDG PET in rheumatoid arthritis: there is still a long way to go. J Nucl Med. 2004;45:927-929.
27. Polisson RP, Schoenberg OI, Fischman A, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:819-825.